Hepatic steatosis as a possible risk factor for the development of hepatocellular carcinoma after eradication of hepatitis C virus with antiviral therapy in patients with chronic hepatitis C

Figure 3 Cumulative incidence of HCC in SVR patients using the log-rank test. A: Patients with age ≥ 55 (black line) and < 55 (gray line) years (P = 0.021); B: Male (black line) and female (gray line) patients (P = 0.389); C: patients with grading of fibrosis, F3-4 (black line) and F1-2 (gray line) (P = 0.0028); D: Patients with pre-treatment ALT levels, ALT > 80 IU (black line) and ≤ 80 IU (gray line) (P = 0.251); E: Patients with the grading of hepatic steatosis, grade 2 (black line), grade 1 (gray line), and grade 0 (gray dotted line) (P = 0.0002 between grade 2 and grade 1 or grade 0).